Autologous, third-generation mesothelin-targeted chimeric antigen receptor T cells that bind mesothelin on tumor cells and signal via CD3z with dual co-stimulatory domains to activate T-cell effector functions, leading to proliferation, cytotoxic killing (perforin/granzyme), and cytokine release; delivered by intratumoral endoscopic ultrasound guidance as neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma.